8-K: ResMed Reports Strong FY2026 Results, Boosts Dividend

ResMed Inc. announced robust fourth quarter and full fiscal year 2026 results, highlighted by record revenue, increased earnings per share, and a 10% hike in its quarterly dividend.

Summary

• ResMed Inc. reported record revenue of $1.5 billion for the fourth quarter of fiscal year 2026, a 9% increase (8% on a constant currency basis) compared to the prior year.
• Full fiscal year 2026 revenue reached $5.7 billion, up 10% (8% on a constant currency basis).
• GAAP diluted earnings per share for Q4 FY2026 were $2.64, a 2% increase, while non-GAAP diluted earnings per share rose 16% to $2.95.
• For the full fiscal year 2026, GAAP diluted earnings per share were $10.43, and non-GAAP diluted earnings per share increased 17% to $11.17.
• The company returned over $1 billion to shareholders in FY2026 through share repurchases and dividends, an increase of over 70%.
• The Board of Directors declared a quarterly cash dividend of $0.66 per share, a 10% increase.
• ResMed announced an agreement to sell its MatrixCare business, expected to close in Q1 FY2027.
• The acquisition of Noctrix Health, a medical device company for Restless Leg Syndrome, was completed.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, improved profitability, and a significant increase in shareholder returns, indicating robust operational performance and confidence in future prospects.

Positives

• Record Q4 revenue of $1.5 billion, up 9% year-over-year (8% constant currency).
• Full year FY2026 revenue of $5.7 billion, up 10% year-over-year (8% constant currency).
• Non-GAAP diluted EPS growth of 16% in Q4 and 17% for the full year.
• Significant increase in shareholder returns, with over $1 billion returned in FY2026 (up over 70%).
• 10% increase in the quarterly cash dividend to $0.66 per share.
• Gross margin expansion: GAAP gross margin up 170 bps to 61.1% for FY2026, non-GAAP up 240 bps to 62.4%.
• Strong operating cash flow of $1.8 billion and free cash flow of $1.6 billion for FY2026.
• Successful completion of the Noctrix Health acquisition.

Negatives

• GAAP diluted earnings per share for Q4 FY2026 saw a modest 2% increase to $2.64.
• Free cash flow for Q4 FY2026 decreased by 21% to $404 million.
• Operating cash flow for Q4 FY2026 decreased by 16% to $455 million.
• The company incurred $41.9 million in Astral field safety notification expenses in Q4 FY2026, impacting GAAP gross margin.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Potential risks include projections of future revenue, earnings, expenses, new product development, new market entries, integration of acquisitions, supply chain issues, regulatory developments, litigation, tax outlook, and macroeconomic conditions.

Future Outlook

The company expects to return more than $1.85 billion to shareholders through share repurchases and dividends in fiscal year 2027. Management aims to leverage global scale and enhance digital capabilities to benefit patients, providers, and customers, using its portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth.

Management Comments

• "We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy," said ResMed's Chairman and CEO, Mick Farrell.
• "Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a 16% increase in earnings per share."
• "For full year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders."
• "As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers."
• "We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders."

Industry Context

StockSavvy.ai notes that ResMed's performance aligns with broader trends in the healthcare technology sector, particularly the increasing demand for connected devices and digital health solutions that improve patient outcomes and reduce healthcare system costs. The company's focus on sleep and respiratory care remains a critical area given the prevalence of these conditions globally.

Stakeholder Impact

• Shareholders: Benefit from a 10% increase in quarterly dividend and continued share repurchases, alongside strong earnings growth.
• Patients: Continued access to innovative sleep and respiratory care technologies aimed at improving health outcomes.
• Providers and Customers: Benefit from enhanced digital capabilities and an improved patient care pathway.
• Employees: Potential for continued investment in innovation and growth, supporting job security and development.

Next Steps

• Close the sale of the MatrixCare business during the first quarter of fiscal year 2027.
• Continue to leverage global scale and enhance digital capabilities in fiscal year 2027.
• Invest in innovation and growth initiatives.
• Return more than $1.85 billion to shareholders through share repurchases and dividends in FY2027.

Key Dates

Recommendation

The filing shows strong operational performance and increased shareholder returns, which are positive indicators. However, the modest GAAP EPS growth, a decrease in Q4 free cash flow, and the impact of field safety notification expenses warrant a cautious approach. While the company is executing well, the current valuation and broader market conditions suggest a 'hold' rating pending further clarity on the integration of acquisitions and sustained growth across all metrics.

Keywords

ResMed, Sleep Apnea, Respiratory Care, Medical Devices, Financial Results, Earnings, Dividend, Acquisition